03999nam 22006495 450 99646648150331620200706122452.03-540-89056-410.1007/978-3-540-89056-0(CKB)1000000000718096(SSID)ssj0000319034(PQKBManifestationID)11264898(PQKBTitleCode)TC0000319034(PQKBWorkID)10337289(PQKB)11240113(DE-He213)978-3-540-89056-0(MiAaPQ)EBC3064122(PPN)134130499(EXLCZ)99100000000071809620100301d2009 u| 0engurnn|008mamaatxtccrModules over Operads and Functors[electronic resource] /by Benoit Fresse1st ed. 2009.Berlin, Heidelberg :Springer Berlin Heidelberg :Imprint: Springer,2009.1 online resource (X, 314 p.) Lecture Notes in Mathematics,0075-8434 ;1967Bibliographic Level Mode of Issuance: Monograph3-540-89055-6 Includes bibliographical references and index.Categorical and operadic background -- Symmetric monoidal categories for operads -- Symmetric objects and functors -- Operads and algebras in symmetric monoidal categories -- Miscellaneous structures associated to algebras over operads -- The category of right modules over operads and functors -- Definitions and basic constructions -- Tensor products -- Universal constructions on right modules over operads -- Adjunction and embedding properties -- Algebras in right modules over operads -- Miscellaneous examples -- Homotopical background -- Symmetric monoidal model categories for operads -- The homotopy of algebras over operads -- The (co)homology of algebras over operads -- The homotopy of modules over operads and functors -- The model category of right modules -- Modules and homotopy invariance of functors -- Extension and restriction functors and model structures -- Miscellaneous applications -- Appendix: technical verifications -- Shifted modules over operads and functors -- Shifted functors and pushout-products -- Applications of pushout-products of shifted functors.The notion of an operad supplies both a conceptual and effective device to handle a variety of algebraic structures in various situations. Operads were introduced 40 years ago in algebraic topology in order to model the structure of iterated loop spaces. Since then, operads have been used fruitfully in many fields of mathematics and physics. This monograph begins with a review of the basis of operad theory. The main purpose is to study structures of modules over operads as a new device to model functors between categories of algebras as effectively as operads model categories of algebras.Lecture Notes in Mathematics,0075-8434 ;1967AlgebraAlgebraic topologyCategory theory (Mathematics)Homological algebraAlgebrahttps://scigraph.springernature.com/ontologies/product-market-codes/M11000Algebraic Topologyhttps://scigraph.springernature.com/ontologies/product-market-codes/M28019Category Theory, Homological Algebrahttps://scigraph.springernature.com/ontologies/product-market-codes/M11035Algebra.Algebraic topology.Category theory (Mathematics).Homological algebra.Algebra.Algebraic Topology.Category Theory, Homological Algebra.512.4218D5055P4818G5518A25mscFresse Benoitauthttp://id.loc.gov/vocabulary/relators/aut472382BOOK996466481503316Modules over operads and functors230303UNISA05879nam 2201945z- 450 991057687430332120220621(CKB)5720000000008432(oapen)https://directory.doabooks.org/handle/20.500.12854/84569(oapen)doab84569(oapen)84569(EXLCZ)99572000000000843220202206d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierAnticancer Drugs 2021BaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (594 p.)3-0365-4348-1 3-0365-4347-3 The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure-activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered.ChemistrybicsscResearch & information: generalbicsscResearch and information: generalbicssc1,2,3-triazole1,3,4-oxadiazole3-amino-4'-guanidino3,4'-bis-guanidino5-fluoruracil7-deaza-4'-thioadenosine derivativesacetamideadamantaneADC (antibody-drug conjugate)agealkylatedanticanceranticancer activityanticancer agentsapoptosisapoptosis inductionaromatase inhibitorBcl-2 inhibitorsbenzenesulfonamidesbenzimidazoleBRAFbreast cancercancercancer cell viabilitycancer vaccineCAR (chimeric antigen receptor)cardiotoxicitycarvedilolcell cycle analysischalconechalconescolony formationcombretastatin A-4concentration-guided dosingcovalent bindingCovDockcumulative dosecyclophosphamidecytotoxic activitycytotoxic agentscytotoxicitydesigned multiple liganddiphenyl etherDNA fragmentationdockingdoxazosindrug effluxdual inhibitorsdual-targeting moleculeEGFRELISAenantioselective synthesisentrectinibexportin-1gastric adenocarcinomageneric productH1299HDAC inhibitorsHER2heterocyclic compoundhistopathologyHL-60HT-29 cellshybrid compoundshybrid moleculehydrazide derivativesimidazolesImiquimodimmunotherapyin vitroin vivoindazoleIndole-based analoguesinflammationinterleukin-6intramolecular hydrogen bondisolationkidneylarotrectinibletrozoleMD simulationsMDA-MB-231 cellsmechanism predictionmiR-21mitoxantronemodel informed dosingMTT cytotoxic assayMUC1MUC16mucinmulti-kinase inhibitormultidrug resistancen/aNaMSAnitrogen scaffoldsNTRKnucleosideoxidative stresspatent reviewpemetrexedphenstatinphenyl pyridyl etherphysiologically based pharmacokineticsprotein kinase inhibitorsresin acidsolid/lipid nanoparticlessorafenibSTAT inhibitorssynthesisTDP1testisthieno[2,3-d][1,2,3]triazinethioureathymidylate synthasetissue-agnosticToll-Like ReceptortoxicityTrkTrk fusiontrypan blue assaytryptophanoltubulin polymerisation inhibitortumor spheroidstyrosil-DNA-phosphodiesterase 1urinary bladderUSFDAxanthoneChemistryResearch & information: generalResearch and information: generalMeegan Mary Jedt1325230O'Boyle Niamh MedtMeegan Mary JothO'Boyle Niamh MothBOOK9910576874303321Anticancer Drugs 20213036711UNINA